IRIDEX Corporation  

(Public, NASDAQ:IRIX)   Watch this stock  
Find more results for IRIX
6.70
+0.01 (0.15%)
Oct 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.62 - 6.92
52 week 5.93 - 11.00
Open 6.63
Vol / Avg. 17,396.00/11,443.00
Mkt cap 64.99M
P/E 40.40
Div/yield     -
EPS 0.17
Shares 9.88M
Beta 1.60
Inst. own 52%
Oct 30, 2014
Q3 2014 IRIDEX Corp Earnings Call
Oct 30, 2014
Q3 2014 IRIDEX Corp Earnings Release
Sep 3, 2014
IRIDEX Corp at Robert W. Baird & Co. Inc Health Care Conference
Aug 12, 2014
IRIDEX Corp at Wedbush Securities Life Sciences Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 2.80% 5.83%
Operating margin 3.78% 6.88%
EBITD margin - 6.92%
Return on average assets 3.65% 7.13%
Return on average equity 4.56% 9.34%
Employees 101 -
CDP Score - -

Address

1212 Terra Bella Avenue
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-9404700 (Phone)
+1-650-9404710 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

IRIDEX Corporation is a worldwide provider of therapeutic based laser systems, delivery devices and consumable instrumentation used to treat eye diseases in ophthalmology. The Company focuses primarily on its ophthalmology. The Company�s ophthalmology products are sold in the United States predominantly through a direct sales force and internationally through approximately 70 independent distributors into over 100 countries. The Company�s ophthalmology offering include IQ and OcuLight laser systems, consumables and service and support activities. The Company �s family of IQ products includes IQ 532, IQ 577 and IQ 810 laser photocoagulation systems and its OcuLight products include OcuLight TX, OcuLight Symphony (Laser Delivery System), OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. In February 2012, The Company sold its aesthetics business to Cutera, Inc.

Officers and directors

William M. Moore Jr. Chairman of the Board, Interim President and Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
James H. Mackaness Chief Financial Officer, Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Ronald T. Steckel Vice President - Operations
Bio & Compensation  - Reuters
Scott A. Shuda Director
Age: 47
Bio & Compensation  - Reuters
Sanford Fitch Independent Director
Age: 73
Bio & Compensation  - Reuters
James B. Hawkins Independent Director
Age: 58
Bio & Compensation  - Reuters
Ruediger Naumann-Etienne Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters